Newly released hepatitis C (HCV) elimination metrics on the HCV Dashboard show that in 2023, 4,783 people were newly diagnosed with HCV in New York State, an 8% decrease from 2022. HCV incidence also continued to decrease, with the rate of new HCV infections dropping from 4.0 to 3.6 new infections per 100,000 population among New Yorkers aged 18-40 from 2022 to 2023. These data, along with HCV treatment/clearance outcomes are all updated through 2023 and available as interactive visualizations on the Dashboard.
Key data highlights:
- Cumulative diagnoses: From 2010 to 2023, nearly 200,000 New Yorkers (199,286) were diagnosed with HCV.
- Gender disparities persist: In 2023, men were nearly twice as likely to be diagnosed with hepatitis C compared to women, with diagnosis rates of 31.5 per 100,000 and 16.2 per 100,000, respectively.
- Age-related trends: Over the past decade, the largest declines in diagnosis rates have been among adults aged 40 and older, highlighted by, the rate among 50–59 year-olds falling from 198.5 per 100,000 in 2014 to 27.6 in 2023.
- Progress toward elimination: As of 2023, 55% of New Yorkers diagnosed with HCV since 2010 have cleared their infection, either through treatment or spontaneously.
The HCV Dashboard now features a new bar chart visualization on the diagnoses and treatment/clearance pages, allowing users to explore a single year’s data by sex and age group across each region in New York State, offering a more granular look at how the epidemic and treatment landscape vary demographically and geographically.
These data demonstrate continued progress toward hepatitis C elimination in New York. Still, disparities remain, highlighting the need for sustained prevention, testing, and treatment efforts.
We invite you to explore these insights and more on the Dashboard’s data page.
